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A B S T R A C T
The skin is an attractive organ for immunization due to the presence of a large number of epidermal and dermal
antigen-presenting cells. Hollow microneedles allow for precise and non-invasive intradermal delivery of vac-
cines. In this study, ovalbumin (OVA)-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles with and
without TLR3 agonist poly(I:C) were prepared and administered intradermally by hollow microneedles. The
capacity of the PLGA nanoparticles to induce a cytotoxic T cell response, contributing to protection against
intracellular pathogens, was examined. We show that a single injection of OVA-loaded PLGA nanoparticles,
compared to soluble OVA, primed both adoptively transferred antigen-speciﬁc naïve transgenic CD8+ and CD4+
T cells with markedly high eﬃciency. Applying a triple immunization protocol, PLGA nanoparticles primed also
endogenous OVA-speciﬁc CD8+ T cells. Immune response, following immunization with in particular anionic
PLGA nanoparticles co-encapsulated with OVA and poly(I:C), provided protection against a recombinant strain
of the intracellular bacterium Listeria monocytogenes, secreting OVA. Taken together, we show that PLGA na-
noparticle formulation is an excellent delivery system for protein antigen into the skin and that protective
cellular immune responses can be induced using hollow microneedles for intradermal immunizations.
1. Introduction
The skin is an organ with many immune cells and is considered a
potent organ for immunizations [1]. However, the challenge is to de-
liver high-molecular-weight antigens across the stratum corneum,
which is the outermost layer of the skin and acts as an eﬀective natural
barrier for penetration of pathogens and allergens into the skin. One of
the methods to circumvent the skin barrier is the use of microneedles.
Microneedles are miniaturized needles that provide the possibility of
minimally invasive vaccination in the dermis and epidermis of the skin.
There are other beneﬁts in using microneedles compared to traditional
hypodermic needles, like possible painless vaccination, the requirement
of less trained personnel and reduced contamination risk [2]. Nowadays
a wide variety of these microneedles exist, including solid, coated,
dissolving and hollow microneedles [3,4].
Hollow microneedles have multiple beneﬁts, for instance they can
be used to inject a wide variety of ﬂuids into the skin at diﬀerent
pressure-driven ﬂow rates [3,5,6] and oﬀer the highest precision in
dose delivery among all microneedle types. Furthermore, they oﬀer the
possibility to screen formulations without time-consuming design and
preparation of microneedles, as in case of coated and dissolving mi-
croneedles. Recently, hollow microneedles and an applicator for them
were developed in our laboratory to inject formulations in precise
manner into the skin. These microneedles were successfully used for
formulations with inactivated polio virus vaccine in rats resulting in
eﬀective humoral immune responses [7–9]. However, whether hollow
microneedle-mediated delivery may also induce CD8+ T cell responses
towards vaccine antigens is presently unclear.
Cytotoxic CD8+ T cells play an important role in cellular immune
protection against intracellular pathogens or tumor growth. To induce
such CD8+ T cell responses, an antigen needs to be processed in the cell
and presented by MHC-I molecules on professional antigen-presenting
cells (pAPC) to the immune system. Delivery of vaccine protein antigens
over the cellular membrane can be achieved using delivery systems and
over the past decades diﬀerent types of them, such as polymeric na-
noparticles, emulsions and lipid-based nanoparticles have been
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developed [10–12]. Nano-encapsulation of antigens has several ad-
vantages, such as stabilization of antigens in vivo, enhancement of the
uptake by pAPC and also reduction of antigen release into systemic
circulation [4,13]. The immune outcome can be potentially shaped by
using nanoparticles with diﬀerence size [14] and surface charge [15],
and by co-encapsulating antigen and adjuvant into the nanoparticles
[16,17].
For the production of polymeric nanoparticles, poly(lactic-co-gly-
colic acid) (PLGA) is the most commonly used polymer, because of its
superior biocompatibility and biodegradability [18–20]. Previous stu-
dies have shown that model antigen- and adjuvant-loaded PLGA na-
noparticles used for vaccination were able to improve the induction of
cell-mediated immune response in mice [17,21–23]. However, rela-
tively little is known about how encapsulation in PLGA nanoparticles
modiﬁes T cell responses to antigen/adjuvant combinations that are
delivered intradermally by diﬀerent novel types of microneedles. One
recent study reported that PLGA nanoparticles, delivered intradermally
using dissolving microneedles arrays [24], induced cellular immune
responses and protection against viral infection and tumor growth.
In this study, nanoparticles were prepared and characterized in
terms of size, surface charge and antigen/adjuvant release proﬁles. We
investigated the ability of hollow microneedle-delivered protein anti-
gens, encapsulated in either anionic or cationic PLGA nanoparticles
without and with co-encapsulated TLR 3 agonist poly(I:C) to induce a
protective, cellular immune response towards an intracellular pathogen
in a mouse model.
2. Materials and methods
2.1. Materials
PLGA (acid terminated, lactide glycolide 50:50, Mw
24.000–38.000), polyethylenimine (PEI, linear, average Mn 10,000),
Roswell Park Memorial Institute medium (RPMI) and Fetal bovine
serum (FBS) were purchased from Sigma-Aldrich (Zwijndrecht, The
Netherlands). PVA 4–88 (31 kDa) was obtained from Fluka (Steinheim,
Germany). Endotoxin-free ovalbumin (OVA), polyinosinic-polycytidylic
acid (poly(I:C)) (low molecular weight) and its rhodamine-labelled
version were obtained from Invivogen (Toulouse, France). Alexa647
labelled OVA (OVA-Alexa647) was ordered from Thermo-Fischer
Scientiﬁc (Waltham, MA). Dimethylsulfoxide (DMSO) was obtained
from Biosolve BV (Valkenswaard, The Netherlands). Sodium dodecyl
sulfate (SDS) was obtained from Merck Millipore (Hohenbrunn,
Germany). Ammonium-Chloride-Potassium (ACK) lysis buﬀer (150 mM
NH4CL, 1 mM NaHCO3; pH 7.40) and 1 mM phosphate buﬀer (PB;
pH 7.4) were prepared in the lab. Milli-Q water (18.2 MΩ/cm, Millipore
Co., USA) was used for the preparation of solutions. Sterile phosphate
buﬀered saline (PBS) was obtained from Braun (Oss, The Netherlands).
All other chemicals used are of analytical grade.
Puriﬁcation antibodies used for DynaBeads® selection were all made
in house and included the following antibody clones: αCD11b (clone
M1/70), αMHC-II (M5/114), αB220 (RA3-6B2), αCD4 (GK1.4), αCD8
(YTS169) and αCD25 (PC61). Puriﬁcation antibodies for sorting via
ﬂow cytometry were αCD8-APC (53-6.7; eBioscience), CD44-FITC
(IM7; eBioscience) and CD62L-PE (MEL-14; BD Bioscience) using a BD
inﬂux (BD Biosciences). For the detection of the adoptively transferred
T cells the antibodies αCD45.2-PerCPCy5.5 (104; eBioscience), αCD4-
PE (GK1.5; eBioscience) and αCD8-APC (53-6.7; BD Bioscience) were
used. Detection of the endogenous T cells was measured using the an-
tibodies αCD8-APC (53-6.7; eBioscience), αCD4-eFluor450 (GK1.5;
eBioscience), αCD62L-Horizon B510 or αCD44-FITC (IM7;
eBioscience), αCD16/CD32-unstained (2.4G2; made in house) and
αIFNγ-PE (XMG1.2; eBioscience).
2.2. Preparation of PLGA nanoparticles
OVA-loaded PLGA nanoparticles were prepared by double emulsion
with solvent evaporation method as previously reported with mod-
iﬁcations [25]. Brieﬂy, 75 μl OVA (20 mg/ml) in PBS was dispersed in
1 ml PLGA (25 mg/ml) in ethyl acetate by a Branson soniﬁer 250
(Danbury, USA) for 15 s with a power of 20 W. To prepare anionic
OVA-loaded PLGA nanoparticles (anPLGA-OVA), the obtained water-in-
oil emulsion was emulsiﬁed with 2 ml 2% (w/v) PVA with the soniﬁer
(15 s, 20 W) to get a water-in-oil-in-water double emulsion. In case of
cationic OVA-loaded PLGA nanoparticles (catPLGA-OVA), the single
emulsion was emulsiﬁed with 2 ml 2% (w/v) PVA and 4% (w/v) PEI
solution. The double emulsion was added dropwise into 25 ml 0.3% (w/
v) PVA (40 °C) under stirring. The ethyl acetate was evaporated by a
rotary evaporator (Buchi rotavapor R210, Switzerland) for 3 h
(150 mbar, 40 °C). The nanoparticle suspension was centrifugated
(Avanti™ J-20XP centrifuge, Beckman Coulter, Brea, CA) at 35000 g for
10 min, washed twice with 1 mM PB to remove the excess OVA and
PVA, and dried in a Alpha1-2 freeze dryer (Osterode, Germany,
−49 °C, 90 mbar) overnight. To prepare OVA and poly(I:C) co-en-
capsulated PLGA nanoparticles (anPLGA-OVA-PIC), 18.75 μl OVA
(40 mg/ml) and 75 μl poly(I:C) (46.7 mg/ml, including 0.03% ﬂuores-
cently labelled equivalent) were emulsiﬁed with 1 ml PLGA (25 mg/ml)
in ethyl acetate to obtain the water-in-oil emulsion. The remaining of
the procedure was identical to that of anPLGA-OVA. The obtained na-
noparticles were stored at 4 °C for analysis and further use. To prepare
the PLGA nanoparticles for release study, 10% of total OVA was re-
placed with OVA-Alexa647 the preparation.
2.3. Characterization of PLGA nanoparticles
The size (Z-average) and polydispersity index (PDI) of nanoparticles
were measured by dynamic light scattering and the zeta potential of
nanoparticles was measured by laser doppler velocimetry using a Nano
ZS® zetasizer (Malvern Instruments, Worcestershire, U.K.). The samples
were diluted with 1 mM PB buﬀer to a nanoparticle concentration of
25 μg/ml before each measurement. To determine the loading eﬃ-
ciency of OVA and poly(I:C) in PLGA nanoparticles, approximately
1 mg of nanoparticles were dissolved in a mixture of 15% (v/v) DMSO
and 85% (v/v) 0.05 M NaOH and 0.5% SDS. The amount of OVA was
determined by MicroBCA method following the manufacturer's in-
structions. The amount of poly(I:C) was quantiﬁed by the ﬂuorescence
intensity of rhodamine labelled poly(I:C) (λex 545 nm/λem 576 nm).
The encapsulation eﬃciency (EE) and loading capacity (LC) of OVA and
poly(I:C) in the nanoparticles were calculated as below:
= ×
M
M
EE% 100%loaded OVA poly(I:C)
totoal ova poly(I:C) (1)
= ×
M
M
LC% 100%loaded OVA poly(I:C)
nanoparticles (2)
where Mloaded OVA/poly(I:C) represents the mass of loaded OVA or poly
(I:C),Mtotal OVA/poly (I:C) is the total amount of OVA or poly(I:C) added to
the formulation and Mnanoparticles is the weight of nanoparticles.
2.4. Release of OVA and poly(I:C) from PLGA nanoparticles
Nanoparticles were prepared in triplicate as described above. To
study the release of OVA and poly(I:C) from PLGA nanoparticles, 3 mg
anPLGA-OVA, catPLGA-OVA or anPLGA-OVA-PIC were dispersed into
1 ml RPMI supplemented with 10% FBS and incubated at 37 °C with a
shaking speed of 350 rpm. At diﬀerent time points, the suspensions
were centrifugated (9000g, 5 min) with Sigma 1–15 centrifuge
(Osterode, Germany). A release sample of 600 μl of the supernatant was
collected and replaced by fresh medium. The released amount of OVA
and poly(I:C) was determined by ﬂuorescence intensity of OVA-
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Alexa647 (λex 647 nm/λem 671 nm) and rhodamine labelled poly(I:C)
(λex 545 nm/λem 576 nm), respectively.
2.5. Mice and intradermal immunizations
8–18 week old male B6·SJL/ptprcaPep3b/BoyCrl (B6·SJL) wild type
mice and 8–30 week old transgenic (tg) mice that express pOVA323–339-
speciﬁc T cell receptor (OT-II mice) or pOVA257–264-speciﬁc T cell re-
ceptor (OT-I mice) were initially obtained from Charles River and were
bred in house. Abdomen of mice were shaved prior to immunization on
both ﬂanks and intradermal immunization was done using a single
hollow microneedle as reported previously [8,9]. The hollow micro-
needle was inserted into the abdomen of mice using an applicator
controlling precisely the depth, volume and rate of the injections. The
injections were performed at a depth of 120 μm, with a volume of 40 μl
in 3 injections (2 right ﬂank, 1 left ﬂank) and with a rate of 10 μl/min.
The depth was increased up to 200 μm if leakage was observed at the
beginning of injection. In all experiments a total of 5 μg OVA or 50 μg
OVA peptides were injected per immunization. In case of anPLGA-OVA-
PIC, the dose of poly(I:C) was also 5 μg. Ethical approval was given by
the Animal Ethics Committee from Utrecht University, The Nether-
lands.
2.6. Adoptive transfer of OVA T cell receptor (TCR) tg T cells
OVA-speciﬁc T cell transferred mice were obtained by injecting OT-I
CD8+ and OT-II CD4+ T cells into wildtype B6·SJL mice. In order to
obtain OT-I and OT-II cells, spleens were isolated from OT-I and OT-II
mice and erythrocyte-depleted splenocytes were obtained as follows.
Single cell suspensions were prepared by passage over a 70 μM cell
strainer after homogenizing the spleens with a syringe plunger, in RPMI
1640 GlutaMAX supplemented with 8.5% fetal calf serum (Bodinco),
30 μM 2-mercaptoethanol and penicillin/streptomycin (complete RPMI
medium). The erythrocytes were depleted by lysis with ACK lysis
buﬀer. Transgenic naïve CD4+ (OT-II) cells and transgenic CD8+ (OT-I)
cells were isolated from splenocytes by negative selection using
Magnetic DynaBeads® (Thermo Fisher Scientiﬁc, Waltham, MA).
Antibodies used were αCD11b, αMHC-II, αB220 and either αCD4 for
CD8 (OT-I) T cell puriﬁcation or αCD8 and αCD25 for naïve CD4+ (OT-
II) T cell puriﬁcation. After negative selection by magnetic beads, a
purity around 70% was achieved for naïve tg CD4+ (OT-II) T cells. An
additional sorting was necessary to separate naïve from non-naïve tg
CD8+ (OT-I) T cells. After selection on CD8+, CD44low and CD62Lhigh
using a BD inﬂux, 100% purity of naïve tg CD8+ (OT-I) T cells was
obtained. Naïve tg CD4+ (OT-II) T cells were stained with carboxy-
ﬂuorescein succinimidyl ester (CFSE; 0.5 μM, Invitrogen) and naïve tg
CD8+ (OT-I) T cells were stained with Cell trace violet (CTV; 5 μM,
Invitrogen) for 10 min at 37 °C. A total of 2 × 106 CFSE-labelled naïve
tg CD4+ T cells and 1 × 106 CTV-labelled naïve tg CD8+ cells were
injected into the tail vein of recipient mice, one day before im-
munization to obtain OVA-speciﬁc T cell transferred mice.
2.7. In vivo proliferation of adoptively transferred T cells
OVA-speciﬁc T cell transferred mice were immunized with OVA,
anPLGA-OVA and catPLGA-OVA at day 0. PBS and OVA peptide im-
munizations were used as negative and positive controls, respectively.
Proliferation of tg T cells was studied at day 3, 5 and 7. Next, 2.5 × 106
erythrocyte depleted splenocytes or draining (inguinal) lymph node
cells were stained with αCD45.2-, αCD4 and αCD8 and transferred cells
were measured as a percentage of CD45.2+ and either CD8+ or CD4+
cells of total cells using a FACSCanto II (BD Biosciences) and FlowJo
(TriStar) analysis software. Percentages of fully proliferated (> 6 divi-
sion) transferred cells were measured by similar antibody staining, but
as CD45.2+ and either CTV−CD4+ and CFSElow or as CFSE−CD8+ and
CTVlow, all after gating on live cells on FSC-A/SSC-A and single cells in
FSC-A/FSC-H.
2.8. Endogenous CD4+ and CD8+ T cell response
B6·SJL mice were immunized with OVA, OVA + poly(I:C), anPLGA-
OVA, catPLGA-OVA or anPLGA-OVA-PIC at day 0, 3, 6 and T cell re-
sponses were analyzed at day 13. The endogenous CD4+ T cell response
was measured by 3H thymidine incorporation. For this 0.2 × 106 ery-
throcyte-depleted splenocytes or inguinal lymph node cells were plated
in complete RPMI medium in a 96 well round bottom plate for 72 h
with or without 10 μg/ml OVA Endo-Fit (Worthigton) or ConA, at 37 °C
in a humidiﬁed incubator. After 72 h, 3H-Thymidine (0.4 μCi/well;
Amersham Biosciences Europe GmbH) was added for an additional 18 h
and incorporation into DNA was measured by liquid scintillation
counting (Microbeta, Perkin-Elmer Inc.).
CD8+ T cell activation was measured using intracellular IFNγ
staining as described previously [26]. In short, 2.5 × 106 erythrocyte-
depleted splenocytes were incubated in complete RPMI medium with
1 μg/ml pOVA257–264 (Genscript) or complete RPMI medium and 10 μM
monensin (eBioscience) for 6 h at 37 °C in 6% humidiﬁed incubator.
Cells were stained with either αCD8 antibody, αCD4, αCD62L or
αCD44 in the presence of αCD16/CD32 to block Fc-receptors. Next,
they were ﬁxed with 2% paraformaldehyde and stained with αIFNγ
antibody in the presence of 0.05% saponin. Samples were measured on
a FACSCanto II (BD Biosciences) and analyzed using FlowJo software
(Tree Star).
2.9. CFU counts in bacterial challenge study
B6·SJL mice were immunized with OVA, OVA + PIC, anPLGA-OVA,
catPLGA-OVA or anPLGA-OVA-PIC at day 0, 3 and 6. Mice were chal-
lenged with recombinant Listeria monocytogenes secreting OVA (rLM-
OVA) 21 days after ﬁnal immunization. Mice immunized with
10.000 CFU rLM-OVA at day 6 were used as positive control and un-
immunized mice served as negative control. rLM-OVA [27,28] were
cultured in Brain Hart Infusion broth (BHI; Sigma-Aldrich) with 5 μg/
ml erythromycin and to challenge the mice 100.000 bacteria from a
LOG-phase culture were injected in 200 μl/mouse in the tail vain. To
study the elimination of bacteria, three days after challenge spleens
were isolated and single cell suspensions were made in RPMI medium.
Serial dilutions were plated on BHI agar plates and CFU counts were
determined after approximately 36 h in a 37 °C incubator. The re-
maining mice were sacriﬁced 5 days after the challenge to study the
CD4+ and CD8+ T cell response. The speciﬁc T cell response was de-
termined in spleen using intracellular IFN-γ staining method as de-
scribed in section 8. To determine the memory phenotype of the CD8+
T cells, CD62L and CD44 antibodies were used. First, in the gate of the
total CD8+ T cells, three diﬀerent populations were gated (Supple-
mentary Fig. 1B; solid lines). CD44− were considered naïve T cells,
CD44+CD62L+ are T central memory cells and CD44+CD62L− are T
eﬀector and T eﬀector memory cells. Second, in order to determine the
antigen speciﬁc memory phenotype, the gates that were set on all CD8+
T cells were copied in the CD8+IFNγ+ population.
2.10. Statistics
Statistical signiﬁcance was determined using Krukal-Wallis and
multiple comparison/post hoc analysis was done with Dunn's correc-
tion, * = p < 0.05, ** = p < 0.01, *** = p < 0.001.
3. Results
3.1. Preparation and characterization of PLGA nanoparticles
The physicochemical characteristics of PLGA nanoparticles are
shown in Table 1. PLGA nanoparticles had a size of approximately
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150 nm with a low PDI ranging from 0.032 to 0.100. AnPLGA-OVA had
a negative surface charge with a zeta potential of approximately
−18 mV and catPLGA-OVA possessed a positive surface charge with an
opposite zeta potential around +10 mV. The EE% of OVA was ap-
proximately 50% in both anPLGA-OVA and anPLGA-OVA-PIC, and
catPLGA-OVA showed a signiﬁcantly higher EE%. CatPLGA-OVA had
also a higher LC% (10.4%) of OVA than anPLGA-OVA (6.6%) and
anPLGA-OVA-PIC (2.8%). The ratio between the initial amounts of OVA
and poly(I:C) in the formulations during the preparation procedure was
adjusted in order to prepare anPLGA-OVA-PIC with similar LC% of OVA
(2.8%) and poly(I:C) (2.7%).
The formulations are characterized in terms of size (diameter) and
poly disperse index (PDI), zeta potential (ZP), and encapsulation eﬃ-
ciency (EE) and loading capacity (LC) of OVA and poly(I:C). The EE% of
OVA or poly(I:C) was deﬁned as the percentage of encapsulated amount
of OVA or poly(I:C) compared to the added amount of OVA or poly(I:C).
The LC% of OVA or poly(I:C) was deﬁned as the percentage of en-
capsulated amount of OVA or poly(I:C) compared to the amount of
nanoparticles. anPLGA-OVA: OVA-loaded PLGA nanoparticles with
negative surface charge. catPLGA-OVA: OVA-loaded PLGA nano-
particles with positive surface charge. anPLGA-OVA-PIC: OVA and poly
(I:C) co-encapsulated anionic PLGA nanoparticles.
3.2. Release of OVA and poly(I:C) from PLGA nanoparticles
Release of OVA and poly(I:C) from PLGA nanoparticles was mea-
sured in vitro in culture medium containing serum (Fig. 1). The de-
veloped nanoparticles showed a burst release of OVA within the ﬁrst
day, followed by a slow release. At day 30 approximately 49%, 22%
and 26% OVA was released from anPLGA-OVA, catPLGA-OVA and
anPLGA-OVA-PIC, respectively. In case of poly(I:C), anPLGA-OVA-PIC
followed the trend of OVA. At day 30, around 42% poly(I:C) was re-
leased. Thus, all of the PLGA nanoparticles released at most one half of
their content within one month time.
3.3. OVA-loaded PLGA nanoparticles enhances antigen-induced activation
of tg T helper cells and enables priming of tg cytotoxic T cells after
intradermal immunization using a hollow microneedle
To determine the induction of a cellular immune response towards a
protein antigen that is delivered via hollow microneedles, we ﬁrst ex-
amined the ability of a protein antigen to activate transgenic (tg) T cells
that were adoptively transferred (Fig. 2A). Naïve OVA speciﬁc CD4+
and CD8+ T cells were isolated from spleens of OT-II and OT-I mice,
expressing a tg T Cell Receptor speciﬁc for the CD4+ and CD8+ T cell
epitopes (OVA323–339 and OVA257–264) of the model antigen OVA, re-
spectively [29,30]. After staining with cell trace dyes, these cells were
mixed and transferred into congenic recipient mice, allowing the dis-
tinction between host and donor T cells in ﬂow cytometry, based on
expression of the congenic marker (Fig. 2A). One day later the recipient
mice were immunized intradermally, using a hollow microneedle, with
full length OVA protein or with the OVA epitopes (pOVA). These epi-
topes do not require any antigen processing in order to activate tg T
cells and served as a positive control. We ﬁrst determined if CD4+ T
helper cells were activated in the present study. Tg CD4+ T cells were
detected in ﬂow cytometry as CD4+ CD45.2+ T cells within the
lymphocyte gate in either draining inguinal lymph nodes (dLN) or in
the spleens. In OVA protein-immunized mice, a small increase in
numbers of tg CD4+ T cells compared to PBS group was found in the
dLN at day 5 after immunization, while in mice immunized with pep-
tides numbers of tg CD4+ T cells were higher in both dLN and spleen
(Fig. 2B). In mice immunized with OVA protein, minimal systemic re-
sponses were measured in the spleen at day 7 (Fig. 2C, F), and fur-
thermore, minimal numbers of transferred CD4+ T cells activated by
OVA protein were fully proliferated (Fig. 2D-F; depicted by> 6 dilu-
tions of cell trace dye).
We then determined whether OVA encapsulation in PLGA nano-
particles could enhance OVA-speciﬁc tg CD4+ T cell responses. When
mice were immunized with OVA-loaded anionic and cationic PLGA
nanoparticles (PLGA-OVA), we detected high numbers of OVA-speciﬁc
tg CD4+ T cells in dLN, both at day 5 and 7 post-immunization
(Fig. 2B). And in spleen these numbers were also signiﬁcantly higher
(Fig. 2C) than in mice immunized with soluble OVA. Total numbers of
tg CD4+ T cells retrieved from PLGA nanoparticle immunized mice
were also much higher than in mice immunized with peptide (Fig. 2B,
C). Over 95% of these cells were fully proliferated in anPLGA-OVA and
catPLGA-OVA groups, while OVA induced only slightly more fully
proliferated cells than PBS locally on day 5 and systemically on day 7.
Immunizing with the OVA peptides showed a high proliferation rate at
day 5 only, while at day 7 the numbers of fully proliferated cells
dropped (Fig. 2E-F). No diﬀerences were observed between responses
Table 1
Physicochemical characteristics of PLGA nanoparticles.
Nanoparticles Size (nm) PDI ZP (mV) EE% LC%
OVA Poly(I:C) OVA Poly(I:C)
anPLGA-OVA 155.0 ± 6.2 0.064 ± 0.010 −18.2 ± 1.7 54.8 ± 1.0 – 6.6 ± 0.1 –
catPLGA-OVA 147.3 ± 2.1 0.100 ± 0.029 9.9 ± 0.5 87.0 ± 4.8 – 10.4 ± 0.6 –
anPLGA-OVA-PIC 148.4 ± 8.4 0.032 ± 0.007 −17.4 ± 0.8 47.2 ± 16.2 9.6 ± 2.8 2.8 ± 1.0 2.7 ± 0.8
Fig. 1. Release of OVA and poly(I:C) from PLGA nanoparticles. PLGA nanoparticles were
dispersed into culture medium containing serum and incubated at 37 °C. At diﬀerent time
points, the release sample was collected to determine the release amount of OVA (A) and
poly(I:C) (B). Data is presented as mean ± SEM, n= 3.
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detected against anPLGA-OVA and catPLGA-OVA. Taken together, we
show that encapsulation in PLGA nanoparticles enhanced the activation
of tg T helper cells by OVA after intradermal immunization using
hollow microneedles.
Next, it was determined if the followed immunization strategy also
induced a cytotoxic cellular immune response, to provide protection
against intracellular pathogens or tumors. Activation and proliferation
of CD8+ tg T cells was measured in the same experimental setup as
shown in Fig. 2A. As expected, no increase in the numbers of tg CD8+ T
cells was detected in either dLN or spleen at day 3, 5 or 7 after im-
munization with soluble OVA protein (Fig. 3A, B). On day 3, im-
munization with OVA induced some T cell proliferation, as shown by
dilution of cell trace dye (Fig. 3C, D), although this proliferation did not
lead to a signiﬁcant increase in tg CD8+ T cell numbers (Fig. 3A, B). In
contrast, immunization with OVA-loaded PLGA nanoparticles, induced
a marked increase in tg CD8+ T cell numbers not only in dLN but also in
spleen, as detected at both days 5 and 7 (Fig. 3A, B). Most of these cells
were fully proliferated and there was no diﬀerence observed between
responses induced by anPLGA-OVA and catPLGA-OVA. Immunization
with OVA peptides also induced a systemic tg CD8+ T cell response,
detected at day 5, but in contrast to nanoparticle-immunization, this
response decreased signiﬁcantly at day 7 in spleen as well as dLN. This
was probably due to diﬀering kinetics of T cell responses triggered by
precise T cell epitopes, compared to full length OVA, which requires
prior antigen processing. In conclusion, our data indicate that en-
capsulation in PLGA nanoparticles enables OVA to trigger CD8+ tg T
cell responses upon hollow microneedle-mediated intradermal delivery.
3.4. OVA primes both endogenous CD4+ and CD8+ T cell responses in
immunized hosts when particulated in PLGA nanoparticles or adjuvanted
with TLR3 agonist
Having shown that hollow microneedle-mediated immunization
with OVA-loaded PLGA nanoparticles activates adoptively transferred
tg T cells (Figs. 2 and 3), we next examined whether this strategy also
primes endogenous T cell responses in immunized hosts. To this end,
wild type mice were immunized at day 0, 3 and 6 with either OVA, OVA
adjuvanted with TLR3 agonist poly(I:C) (OVA + PIC), anPLGA-OVA,
catPLGA-OVA or anPLGA-OVA-PIC (Table 1; Fig. 4A).
At day 13, antigen-speciﬁc CD8+ T cell responses were detected by
intracellular IFNγ cytokine staining (Supplementary Fig. 1A).
Background levels of IFNγ produced by CD8+ T cells was low in all
mice, as depicted by restimulation of cells with medium (Fig. 4B, C). As
expected, no OVA257–264-speciﬁc CD8+ T cell response was detected in
mice immunized with soluble OVA (Fig. 4B, C). In contrast, responses to
this epitope were clearly detectable in dLN (Fig. 4B) and the spleen
(Fig. 4C) of mice immunized with either OVA + PIC, as well as
catPLGA-OVA or anPLGA-OVA. Responses in the anPLGA-OVA mouse
group tended to be lower than in the catPLGA-OVA group. The addition
of poly(I:C) enhanced the response induced by anPLGA-OVA im-
munization, although OVA-PIC only already showed some CD8 acti-
vation as well (Fig. 4B, C). Thus, following hollow microneedle-medi-
ated delivery, a speciﬁc recipient CD8+ T cell response is induced by
OVA when encapsulated in cationic PLGA nanoparticles or when ad-
juvanted with TLR3 agonist with or without anionic PLGA nano-
particles.
Furthermore, induction of OVA-speciﬁc CD4+ T cell responses in
the immunized mice was determined by measuring 3H–thymidine in-
corporation in 72 h splenocyte cultures incubated with OVA protein.
Some OVA-speciﬁc proliferation was detected in mice immunized with
OVA + PIC, catPLGA-OVA, and anPLGA-OVA-PIC (Fig. 4D), although
no signiﬁcant diﬀerences between groups were observed.
Thus, hollow microneedle-mediated, intradermal immunization
with PLGA nanoparticle encapsulated OVA with or without poly(I:C)
induces clearly detectable OVA257–264-speciﬁc CD8+ T cell responses
and minor OVA-speciﬁc CD4+ T cell responses in mice.
Fig. 2. Encapsulation of OVA by PLGA nanoparticles enhances activation of tg CD4+ T cells after intradermal immunization using hollow microneedle.
(A) Experimental design; naïve CD8+ tg T cells speciﬁc for OVA257–264 were isolated from spleens of OT-I mice and stained with Cell Trace Violet. CD4+ tg T cells speciﬁc for OVA323–339
were isolated from spleens of OT-II mice and stained with carboxyﬂuorescein succinimidyl ester (CFSE). From both cell types 1 × 106 cells were injected in tail vain of B6·SJL mice 1 or
2 days before intradermal immunization. T cell responses were analyzed on day 3, 5 and 7. (B–F) CD4+ T cell response of tg transferred T cells. (B–C) Amount of transferred tg T cells as
percentage of CD45.2+CD4+ cells in either dLN cells or lymphocyte gate of splenocytes. (D) Indication of fully proliferated (> 6 dilutions) cells in the CFSE window of CTV−/
CD45.2+CD4+/lymphocyte gate. (E–F) Percentage of cells that are CD45.2+CD4+ and divided> 6 times as measured by CFSE intensity on day 5 or 7 in either dLN (E) or spleen (F) after
intradermal immunization via hollow microneedles with the formulations indicated on x axes. Graphs are representative for 1 of total 2 independent experiments. Per experiment the
number of mice used is n= 4 for OVA, anPLGA-OVA and catPLGA immunization groups, n= 3 for pOVA immunization groups, n= 2 for PBS immunization group (as depicted by the
number of symbols in the graph). Statistical signiﬁcance was determined using Kruskal-Wallis, p < 0.05 and multiple comparison/post hoc analysis was done comparing immunization
strategies versus PBS or OVA immunization with Dunn's correction, *p < 0.05.
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3.5. Protective immune response towards recombinant rLM-OVA after
intradermal immunization using hollow microneedles
CD8+ T cells play an essential role in clearance of the intracellular
bacterium Listeria monocytogenes [31]. Next, we determined whether
hollow microneedle-mediated vaccination with PLGA nanoparticles
induces protective immunity against rLM-OVA. Mice were immunized
with OVA, OVA-PIC, anPLGA-OVA, catPLGA-OVA or anPLGA-OVA-PIC
at day 0, 3 and 6 and challenged with the bacterium, 21 days after ﬁnal
immunizations (Fig. 5A). Unimmunized mice served as a negative
control and mice immunized with rLM-OVA at day 6 served as positive
control, as these mice are typically able to completely clear the bac-
terium within 3 days after challenge. Determination of CFU counts in
the spleens at day 30 showed that mice immunized with rLM-OVA in-
deed completely cleared the challenge dose, while spleens of non-im-
munized mice contained on average approximately 100.000 bacteria
(Fig. 5B). While immunization with soluble OVA, anPLGA-OVA or OVA-
PIC failed to protect (Fig. 5B), protection was observed in at least one
mouse immunized with catPLGA-OVA. Moreover, anPLGA-OVA-PIC
induced full protection, resulting in zero bacteria count in the spleen,
similar to mice immunized with rLM-OVA. This indicates that im-
munization with anPLGA-OVA-PIC, and to some degree catPLGA-OVA,
via the intradermal route using hollow microneedles, elicits a protective
cellular immune response.
To study the possible relation between T cell response and the ca-
pacity to clear the pathogen, the T cell response in the spleen of the
mice was measured. Quantiﬁcation of T cell responses 5 days after
challenge with rLM-OVA showed that all immunization regimens
triggered OVA-speciﬁc CD4+ T cell responses, and that poly(I:C) did
not further increase these responses (Fig. 5C). In all immunized groups
except for OVA-immunized mice a particularly robust activation of
antigen-speciﬁc CD8+ T cells was detected (Fig. 5D). Remarkably, the
minor population of activated CD8+ T cells in OVA-immunized mice
consisted of 40% central memory T cells (Tcm; CD62L+CD44+) and
60% eﬀector T cells and eﬀector memory T cells (Teﬀ/Tem;
CD62L−CD44+). In contrast, in the other immunization groups the
Tcm populations were much smaller and the Teﬀ/Tem cell population
much larger (Supplementary Fig. 1B–D; solid line). While Tcm:Teﬀ/
Tem cell ratio failed to correlate with immune protection, cells within
the CD62L−CD44+gate were further analyzed (Supplementary
Fig. 1B–D; dotted line). We found higher CD44int:CD44hi cell ratios in
mice that had received anPLGA-OVA-PIC, catPLGA-OVA and rLM-OVA,
i.e. the immunization regimens that led to reduced CFU counts fol-
lowing bacterial challenge (Fig. 5E). Thus, the presence of antigen-
speciﬁc CD44int CD8+ T cells seems favorable for immune protection to
rLM-OVA infection.
4. Discussion
Nowadays, most of the vaccines under investigation are based on
recombinant proteins or subunits of pathogens, because of improved
safety and lower production cost compared to live or attenuated vac-
cines [32]. However, generally such vaccines are poorly immunogenic
and fail to elicit robust cell-mediated immunity against intracellular
pathogens. In this respect, nanoparticle-based delivery of antigens may
be an attractive tool, because it can improve immune response
Fig. 3. Encapsulation of OVA by PLGA nanoparticles enables activation of tg CD8+ T cells after intradermal immunization using hollow microneedle.
CD8+ T cell response of tg transferred T cells. (A, B) Amount of transferred tg T cells as percentage of CD45.2+CD8+ cells in either dLN cells or lymphocyte gate of splenocytes. (C, D)
Percentage of cells that are CD45.2+CD8+ and divided> 6 times as measured by Cell Trace Violet intensity on day 3, 5 or 7 in either dLN (C) or spleen (D) after intradermal
immunization via hollow microneedles with the formulations indicated on X-axes. Graphs are representative for 1 of total 2 independent experiments. Per experiment the number of mice
used is n= 4 for OVA, anPLGA-OVA and catPLGA immunization groups, n = 3 for pOVA immunization groups, n= 2 for PBS immunization group (as depicted by the number of symbols
in the graph). Statistical signiﬁcance was determined using Kruskal-Wallis, p < 0.05 and multiple comparison/post hoc analysis was done comparing immunization strategies versus PBS
immunization with Dunn's correction, *p < 0.05.
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induction to encapsulated antigens [33]. In this study, OVA was used as
a model antigen and encapsulated into PLGA nanoparticles with or
without the adjuvant poly(I:C). The capacity of the nanoparticle for-
mulations to stimulate cell-mediated immunity was investigated by
intradermal immunization using hollow microneedles. In this study, we
show that intradermal delivery using hollow microneedles can elicit a
protective cellular immune response when the antigen is encapsulated
in cationic or adjuvanted anionic PLGA nanoparticles. These data ex-
pand on previous studies using hollow microneedles where humoral
immune responses were detected [7–9], which illustrated the attrac-
tiveness of the intradermal route for the delivery of vaccines. In our
studies, we elaborated on the potential to induce CD8+ T cells in the
skin using microneedles, speciﬁcally using hollow microneedles.
Nanocarriers used for delivery of proteins or subunit vaccines en-
hance antigen uptake by antigen presenting cells and contribute to a
prolonged presentation of the vaccine antigen at the cell surface
[34,35]. This leads to activation of a cellular immune response, which
was exempliﬁed in previous studies showing that PLGA nanoparticle-
encapsulated antigens, with or without adjuvant, may induce strong T
helper type 1 and cytotoxic T cell immune response (Th1/CTL) response
when delivered systemically or subcutaneously [15,17,36]. However,
relatively little is known about the immune responses elicited by na-
noparticle vaccines when administered intradermally using micro-
needles. On the one hand, inducing conduits in the skin with micro-
needles and subsequent application of nanoparticles, loaded with either
OVA or antigen-encoding cDNA, induced an immune response [37,38].
Nevertheless, this method of delivery diﬀers from intradermal admin-
istration by microneedles. On the other hand, some previous studies on
model subunit vaccines using microneedles, such as nanopatches to
deliver non-encapsulated TLR adjuvants or pH sensitive microneedles
arrays loaded with high doses of protein induced CD8+ T cell re-
sponses [39–41]. However, in these studies using microneedles none of
the vaccine antigens were encapsulated in nanoparticles. In one study,
dissolving microneedles loaded with PLGA nanoparticle encapsulated
antigens were used for intradermal vaccination, and shown to induce a
robust antigen-speciﬁc protective cellular immune response in mice
[24].
Our data show that hollow microneedle-delivered nanoencapsu-
lated OVA not only activated transferred tg T cells, but also primed
endogenous protective CD8+ T cell responses in immunized mice. In
mice adoptively transferred with tg T cells, an endogenous T cell re-
sponse could not be detected (not shown). This may be explained by the
single injection immunization regimen in these studies, which may be
suﬃcient to prime adoptively transferred tg CD8+ T cells, but not the
naïve antigen-speciﬁc T cell repertoire. Alternatively, interference of
the relatively easily activated tg T cells with priming of naïve T cells of
recipient mice, for example by cytotoxicity towards antigen presenting
pAPC as part of an immune homeostasis feedback loop, may also ex-
plain this observation. For this reason, to examine whether hollow
microneedle-mediated immunization with PLGA nanoparticles en-
capsulated OVA may prime OVA-speciﬁc endogenous CD8+ T cells in
mice, a priming procedure was used consisting of three immunizations
delivered over a time period of 6 days. This protocol had been shown to
induce cellular immune responses following dermal DNA tattoo im-
munization [26,42], but not yet when using hollow microneedles [7].
We report here that this prime boost protocol indeed elicits vigorous
Fig. 4. Speciﬁc endogenous T cell responses induced by OVA when particulated in anionic or cationic PLGA nanoparticles or when adjuvanted with TLR3 agonist.
(A) Schematic overview of immunization strategy of measuring wild type T cell responses. Intradermal immunization on day 0, 3 and 6 and responses measured 7 days after ﬁnal
immunization (day 13). (B, C) Percentage of IFNy+ cells in CD8+ gate within the lymphocyte gate on FSC/SSC of dLN (B) or spleens (C) depicted in black symbols. IFNy+ cells upon
stimulation with medium is considered background and shown in gray. Results were pooled of 2 experiments with a total of 6–9 mice/group. (D) CD4+ T cell response was measured by
proliferation of splenocytes upon stimulation of OVA protein. Incorporation of 3H-thymdine in DNA was measured liquid scintillation counting as CCTM. Statistical signiﬁcance was
determined using Kruskal-Wallis, p < 0.05 and multiple comparison/post hoc analysis was done comparing all immunization groups with Dunn's correction, *p < 0.05, **p < 0.01,
***p < 0.001.
A.M. de Groot et al. Journal of Controlled Release 266 (2017) 27–35
33
CD8+ T cell responses in mice immunized with PLGA encapsulated
antigen, when using hollow microneedles as delivery method.
A variety of dendritic cells in the dermis and epidermis have been
shown to contribute to immune activation following dermal im-
munization [43,44], and they all express diverse pathogen recognition
receptors, such as Toll-like receptors (TLRs). In agreement with this
observation, multiple intradermal immunization studies using diﬀerent
administration methods have shown added eﬀects of diﬀerent Toll-like
receptor (TLR) agonists based adjuvants [16,45]. In our study, co-de-
livery of OVA and the TLR3 agonist poly(I:C) in PLGA nanoparticles, led
to protective cellular immune responses to rLM-OVA. Possibly, the
nanoparticles act as a depot system and stimulate the immune system
by controlling the release of OVA and poly(I:C), resulting in prolonged
OVA presentation and enhanced immunogenicity [23].
Positively charged cationic PLGA nanoparticles are considered to be
more immunogenic than anionic PLGA nanoparticle, as their positive
surface charge facilitate the interaction with anionic cell membranes,
enhancing uptake of these nanoparticles by phagocytic cells [46].
However, this enhanced interaction can also lead to increased cell cy-
totoxicity [10], contributing to the challenges faced for therapeutic use
in humans. In our adoptive transfer studies anPLGA-OVA and catPLGA-
OVA seemed to perform equally well. However, catPLGA-OVA primed
the endogenous cellular immune responses eﬃciently, while anPLGA-
OVA did not show signiﬁcant increase of response compared to OVA.
Although one mouse showed full protection from subsequent infection
with rLM-OVA after immunization with catPLGA-OVA, no statistical
diﬀerence in degree of immune protection induced by cationic com-
pared to anionic PLGA-OVA was detected. Inclusion of poly(I:C) in the
anionic nanoparticles was needed to fully protect immunized mice from
infection.
Remarkably, although immune protection diﬀered between mice
immunized with OVA particulated in cationic or anionic PLGA without
or with poly(I:C), vigorous OVA-speciﬁc CD8+ T cell responses were
detected in all mouse groups except for mice immunized with soluble
OVA. Diﬀerence in antigen release can have a role in shaping the
memory phenotype [47], however we found similar release proﬁles.
Further analysis of CD8+ T cell phenotype showed that there was no
diﬀerence within percentage of Tcm and Tem/Teﬀ cells between the
diﬀerent PLGA NP immunized groups, but an enhanced ratio of CD8+ T
cells with CD44int phenotype was detected in mice immune to rLM-OVA
challenge. Thus, although no clear deﬁnition of CD44intCD62Lneg is
available [48–50], we show a correlation between their presence and
intradermal immunization-induced protective immunity to challenge
with rLM-OVA.
Taken together, we show that hollow microneedles are an excellent
tool for intradermal vaccination, leading to the induction of minor
CD4+ T cell and vigorous CD8+ T cell responses to PLGA nanoparticle
encapsulated antigens. Evoked CD8 T+ cell responses provided pro-
tection against an intracellular bacterium if poly(I:C) was co-en-
capsulated with the OVA antigen. Future studies may show whether
other adjuvants have similar eﬀects or whether speciﬁc adjuvants may
induce protection to speciﬁc categories of intracellular pathogens.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jconrel.2017.09.017.
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Fig. 5. Protective immune response towards rLM-OVA after
hollow microneedle mediated intradermal immunization
(A) Schematic overview of challenge study in which the
mice received an i.v. challenge of 100.000 recombinant
Listeria monocytogenes-OVA 21 days after 3 immunizations
with OVA with or without negatively or positively charged
PLGA NP or with or without poly(I:C). CFU count of rLM-
OVA in spleen was determined 3 days after challenge and T
cell activation was measured 5 days after challenge. (B)
Spleens were isolated and serial dilutions were plated on
BHI agar plates and CFU's were counted 36 h after in-
cubation at 37 °C. (C) CD4+ T cell and (D + E) CD8+ T cell
responses were measured identical to procedure Fig. 3B+D
in spleens. Gentamycin was added to culture medium to
prevent further growth of potential rLM-OVA. Per experi-
ment n= 4 for OVA, anPLGA-OVA and catPLGA im-
munization groups, n= 3 for pOVA immunization groups,
n= 2 for PBS immunization group (as depicted by the
number of symbols in the graph). Statistical signiﬁcance
was determined using Kruskal-Wallis, p < 0.05 and mul-
tiple comparison/post hoc analysis was done with Dunn's
correction, *p < 0.05.
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